Latest Non-steroidal anti-inflammatory drugs Stories
NASHVILLE, Tenn., July 12 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc.
Reporting in the journal Urology, researchers at Thomas Jefferson University have found that a pre-emptive multimodal pain regimen that included pregabalin (Lyrica) decreased the use of opioid analgesics in patients undergoing robotic-assisted laparoscopic radical prostatectomy.
Separate study reveals that early control of inflammation in patients with RA arthritis important in reducing cardiovascular risk.
Four out of ten high-risk patients prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) also received appropriate measures to prevent upper-gastrointestinal (UGI) problems, but the remainder did not receive adequate protection.
NEW YORK, June 17 /PRNewswire-FirstCall/ -- Pfizer Inc.
Gels, creams and sprays containing painkillers such as ibuprofen, diclofenac, ketoprofen, and piroxicam are safe and effective treatments for local pain, according to Cochrane Researchers.
NORTHBROOK, Ill., June 9 /PRNewswire/ -- Horizon Pharma, Inc., today announced that data on its two lead product candidates, LODOTRAÂ®, a circadian cytokine modulator and novel modified release, low-dose prednisone tablet, and DUEXAÂ®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, will be presented during the European League Against Rheumatism (EULAR) Annual Congress taking place in Rome, Italy, June 16-19.
BRIDGEWATER, N.J., June 8 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in New Jersey, announced today that CAMBIA(TM) (diclofenac potassium for oral solution) is now available in the United States for the acute treatment of migraine with or without aura.
Lead Candidate, LT-NS001, Shows Evidence of Improved GI Safety for Arthritis Patients WALTHAM, Mass., May 26 /PRNewswire/ -- Logical Therapeutics, Inc., a private, clinical stage biopharmaceutical company, announced today it had closed on a $16.9 million Series C equity financing.
NORTHBROOK, Ill., May 26 /PRNewswire/ -- Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXAÂ®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S.
More Images (1 images) »